Cytogenetic and Genome Research

Novel Insights from Clinical Practice

García-Romero A.a,b· González-Arreola R.M.a,b· Borjas-Gutiérrez C.c· Magaña-Torres M.T.b· González-García J.R.b

Author affiliations

aDoctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico
bDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
cServicio de Hematología, UMAE Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 10, 2022
Accepted: October 04, 2022
Published online: February 01, 2023

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)

For additional information: https://www.karger.com/CGR

Abstract

Acute promyelocytic leukemia (APL) is characterized by the chromosomal translocation t(15;17)(q24;q21), raising two hybrid genes: PML::RARA and RARA::PML. There is a biased clonal evolution in APL since imbalances affecting the der(15) chromosome (the one that carries the transforming PML::RARA gene) have never been reported; instead, imbalances of the der(17), mainly in form of an ider(17)(q10), have been repeatedly documented. We here present two cases with APL who acquired an ider(17)(q10) as a secondary chromosomal change. The presence of the ider(17)(q10) implies several genomic consequences with potential to fuel tumor progression: (1) a duplication of the hybrid gene RARA::PML; (2) a cumulative haploinsufficiency for tumor suppressor genes located in the 17p arm; and (3) a cumulative triplosensitivity of genes located in 17q10→RARA::PML→15qter. Both our patients were treated following the PETHEMA LPA 2012 protocol with ATRA plus idarubicin and they have had a long event-free survival.

© 2023 S. Karger AG, Basel

References Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, et al. Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1992;89(11):4840–4. Berger R, Coniat ML, Derré J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer. 1991;3(5):332–7. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol. 1992;82(3):529–40. Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424–31. Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015. Chou WC, Tang JL, Yao M, Liang YJ, Lee FY, Lin MT, et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia. 1997;11(7):921–8. Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016;30(10):1987–92. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013;155(4):948–62. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6. de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–60. Grimwade D, Howe K, Langabeer S, Davis L, Oliver F, Walker H, et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol. 1996;94(3):557–73. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood. 2000;96(4):1297–308. Guo M, Xiao ZD, Dai Z, Zhu L, Lei H, Diao LT, et al. The landscape of long noncoding RNA-involved and tumor-specific fusions across various cancers. Nucleic Acids Res. 2020;48(22):12618–31. He Y, Wang P, Liang K, Chen X, Du W, Li J, et al. A pediatric acute promyelocytic leukemia with a rare karyotype of ider(17)(q10)t(15;17) and favorable outcome: a case report. Medicine (Baltimore). 2015;94(41):e1778. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol. 1997;96(2):314–21. Hu X, Ai G, Meng X, Hou J, Wei R, Tao Y, et al. An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia. Cancer Genet. 2014;207(6):253–7. Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, et al. Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia. JCO Oncol Pract. 2021;17(4):e497–e505. Kaleem Z, Watson MS, Zutter MM, Blinder MA, Hess JL. Acute promyelocytic leukemia with additional chromosomal abnormalities and absence of Auer rods. Am J Clin Pathol. 1999;112(1):113–8. Kim MJ, Cho SY, Lim G, Yoon HS, Lee HJ, Suh JT, et al. A rare case of microgranular acute promyelocytic leukemia associated with ider(17)(q10)t(15;17) in an old-age patient. Ann Lab Med. 2011;31(2):86–90. Lafage-Pochitaloff M, Alcalay M, Brunel V, Longo L, Sainty D, Simonetti J, et al. Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes. Blood. 1995;85(5):1169–74. Li YP, Andersen J, Zelent A, Rao S, Paietta E, Tallman MS, et al. RARα1/RARα2-PML mRNA expression in acute promyelocytic leukemia cells: a molecular and laboratory-clinical correlative study. Blood. 1997;90(1):306–12. Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel). 2020;12(3):624. Liu Y, Xu J, Chu L, Yu L, Zhang Y, Ma L, et al. A rare case of acute promyelocytic leukemia with ider(17)(q10)t(15;17)(q22;q21) and favorable outcome. Mol Cytogenet. 2020;13(1):13. Manola KN, Karakosta M, Sambani C, Terzoudi G, Pagoni M, Gatsa E, et al. Isochromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA/PML fusion gene: report of 4 cases and review of the literature. Acta Haematol. 2010;123(3):162–70. McGowan-Jordan J, Hastings RJ, Moore S, editors. ISCN 2020: An International System for Human Cytogenomic Nomenclature. Basel: S. Karger; 2020. Mitelman F, Johansson B, Mertens F, editors. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2022. [last updated on June 6, 2022; cited June 20, 2022] https://mitelmandatabase.isb-cgc.org Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1999;96(26):15103–8. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100. Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, et al. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015;94(8):1347–56. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94(3):493–500. Stavropoulou C, Georgakakos VN, Manola KN, Pagoni M, Garofalaki M, Pantelias GE, et al. 5’RARA submicroscopic deletion from new variant translocation involving chromosomes 15, 17, and 18, in a case of acute promyelocytic leukemia. Cancer Genet Cytogenet. 2008;182(1):50–5. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C, et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia. 2001;15(9):1359–68. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2000;97(24):13306–11. Article / Publication Details

First-Page Preview

Received: August 10, 2022
Accepted: October 04, 2022
Published online: February 01, 2023

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)

For additional information: https://www.karger.com/CGR

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.